Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Feb;40(2):503–505. doi: 10.1128/aac.40.2.503

Emergence of fluoroquinolone-resistant Escherichia coli in fecal flora of cancer patients receiving norfloxacin prophylaxis.

J Carratala 1, A Fernandez-Sevilla 1, F Tubau 1, M A Dominguez 1, F Gudiol 1
PMCID: PMC163147  PMID: 8834911

Abstract

We studied 122 stool samples collected from 25 patients with hematologic malignancies who received prophylactic norfloxacin. Fecal samples were obtained at admission and twice weekly thereafter during prophylaxis. Fluoroquinolone-resistant Escherichia coli strains were isolated from the feces of 10 (40%) of the patients; two patients had fluoroquinolone-resistant E. coli strains prior to beginning norfloxacin treatment, and in the other eight patients, the strains appeared subsequently. One patient developed fluoroquinolone-resistant E. coli bacteremia after 10 days of norfloxacin administration.

Full Text

The Full Text of this article is available as a PDF (219.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barrett T. J., Lior H., Green J. H., Khakhria R., Wells J. G., Bell B. P., Greene K. D., Lewis J., Griffin P. M. Laboratory investigation of a multistate food-borne outbreak of Escherichia coli O157:H7 by using pulsed-field gel electrophoresis and phage typing. J Clin Microbiol. 1994 Dec;32(12):3013–3017. doi: 10.1128/jcm.32.12.3013-3017.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bodey G. P. Antimicrobial prophylaxis for infection in neutropenic patients. Curr Clin Top Infect Dis. 1988;9:1–43. [PubMed] [Google Scholar]
  3. Bow E. J., Loewen R., Vaughan D. Reduced requirement for antibiotic therapy targeting gram-negative organisms in febrile, neutropenic patients with cancer who are receiving antibacterial chemoprophylaxis with oral quinolones. Clin Infect Dis. 1995 Apr;20(4):907–912. doi: 10.1093/clinids/20.4.907. [DOI] [PubMed] [Google Scholar]
  4. Bow E. J., Rayner E., Louie T. J. Comparison of norfloxacin with cotrimoxazole for infection prophylaxis in acute leukemia. The trade-off for reduced gram-negative sepsis. Am J Med. 1988 May;84(5):847–854. doi: 10.1016/0002-9343(88)90062-9. [DOI] [PubMed] [Google Scholar]
  5. Bow E. J., Ronald A. R. Antibacterial chemoprophylaxis in neutropenic patients--where do we go from here? Clin Infect Dis. 1993 Sep;17(3):333–337. doi: 10.1093/clinids/17.3.333. [DOI] [PubMed] [Google Scholar]
  6. Carratalá J., Fernández-Sevilla A., Tubau F., Callis M., Gudiol F. Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis. 1995 Mar;20(3):557–563. doi: 10.1093/clinids/20.3.557. [DOI] [PubMed] [Google Scholar]
  7. Classen D. C., Burke J. P., Ford C. D., Evershed S., Aloia M. R., Wilfahrt J. K., Elliott J. A. Streptococcus mitis sepsis in bone marrow transplant patients receiving oral antimicrobial prophylaxis. Am J Med. 1990 Oct;89(4):441–446. doi: 10.1016/0002-9343(90)90373-l. [DOI] [PubMed] [Google Scholar]
  8. Cometta A., Calandra T., Bille J., Glauser M. P. Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. N Engl J Med. 1994 Apr 28;330(17):1240–1241. doi: 10.1056/NEJM199404283301717. [DOI] [PubMed] [Google Scholar]
  9. Donnelly J. P., Maschmeyer G., Daenen S. Selective oral antimicrobial prophylaxis for the prevention of infection in acute leukaemia-ciprofloxacin versus co-trimoxazole plus colistin. The EORTC-Gnotobiotic Project Group. Eur J Cancer. 1992;28A(4-5):873–878. doi: 10.1016/0959-8049(92)90138-r. [DOI] [PubMed] [Google Scholar]
  10. Elting L. S., Bodey G. P., Keefe B. H. Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin Infect Dis. 1992 Jun;14(6):1201–1207. doi: 10.1093/clinids/14.6.1201. [DOI] [PubMed] [Google Scholar]
  11. Giuliano M., Pantosti A., Gentile G., Venditti M., Arcese W., Martino P. Effects on oral and intestinal microfloras of norfloxacin and pefloxacin for selective decontamination in bone marrow transplant patients. Antimicrob Agents Chemother. 1989 Oct;33(10):1709–1713. doi: 10.1128/aac.33.10.1709. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Gualtieri R. J., Donowitz G. R., Kaiser D. L., Hess C. E., Sande M. A. Double-blind randomized study of prophylactic trimethoprim/sulfamethoxazole in granulocytopenic patients with hematologic malignancies. Am J Med. 1983 Jun;74(6):934–940. doi: 10.1016/0002-9343(83)90785-4. [DOI] [PubMed] [Google Scholar]
  13. Jansen J., Cromer M., Akard L., Black J. R., Wheat L. J., Allen S. D. Infection prevention in severely myelosuppressed patients: a comparison between ciprofloxacin and a regimen of selective antibiotic modulation of the intestinal flora. Am J Med. 1994 Apr;96(4):335–341. doi: 10.1016/0002-9343(94)90063-9. [DOI] [PubMed] [Google Scholar]
  14. Karp J. E., Merz W. G., Hendricksen C., Laughon B., Redden T., Bamberger B. J., Bartlett J. G., Saral R., Burke P. J. Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1987 Jan;106(1):1–7. doi: 10.7326/0003-4819-106-1-1. [DOI] [PubMed] [Google Scholar]
  15. Kern W. V., Andriof E., Oethinger M., Kern P., Hacker J., Marre R. Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother. 1994 Apr;38(4):681–687. doi: 10.1128/aac.38.4.681. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Lew M. A., Kehoe K., Ritz J., Antman K. H., Nadler L., Kalish L. A., Finberg R. Ciprofloxacin versus trimethoprim/sulfamethoxazole for prophylaxis of bacterial infections in bone marrow transplant recipients: a randomized, controlled trial. J Clin Oncol. 1995 Jan;13(1):239–250. doi: 10.1200/JCO.1995.13.1.239. [DOI] [PubMed] [Google Scholar]
  17. Liang R. H., Yung R. W., Chan T. K., Chau P. Y., Lam W. K., So S. Y., Todd D. Ofloxacin versus co-trimoxazole for prevention of infection in neutropenic patients following cytotoxic chemotherapy. Antimicrob Agents Chemother. 1990 Feb;34(2):215–218. doi: 10.1128/aac.34.2.215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Murray B. E., Rensimer E. R., DuPont H. L. Emergence of high-level trimethoprim resistance in fecal Escherichia coli during oral administration of trimethoprim or trimethoprim--sulfamethoxazole. N Engl J Med. 1982 Jan 21;306(3):130–135. doi: 10.1056/NEJM198201213060302. [DOI] [PubMed] [Google Scholar]
  19. Peña C., Albareda J. M., Pallares R., Pujol M., Tubau F., Ariza J. Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections. Antimicrob Agents Chemother. 1995 Feb;39(2):520–524. doi: 10.1128/aac.39.2.520. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Rozenberg-Arska M., Dekker A. W., Verhoef J. Ciprofloxacin for selective decontamination of the alimentary tract in patients with acute leukemia during remission induction treatment: the effect on fecal flora. J Infect Dis. 1985 Jul;152(1):104–107. doi: 10.1093/infdis/152.1.104. [DOI] [PubMed] [Google Scholar]
  21. Talbot G. H., Cassileth P. A., Paradiso L., Correa-Coronas R., Bond L. Oral enoxacin for infection prevention in adults with acute nonlymphocytic leukemia. The Enoxacin Prophylaxis Study Group. Antimicrob Agents Chemother. 1993 Mar;37(3):474–482. doi: 10.1128/aac.37.3.474. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Tancrède C. H., Andremont A. O. Bacterial translocation and gram-negative bacteremia in patients with hematological malignancies. J Infect Dis. 1985 Jul;152(1):99–103. doi: 10.1093/infdis/152.1.99. [DOI] [PubMed] [Google Scholar]
  23. Wade J. C., Schimpff S. C., Hargadon M. T., Fortner C. L., Young V. M., Wiernik P. H. A comparison of trimethoprim-sulfamethoxazole plus nystatin with gentamicin plus nystatin in the prevention of infections in acute leukemia. N Engl J Med. 1981 Apr 30;304(18):1057–1062. doi: 10.1056/NEJM198104303041801. [DOI] [PubMed] [Google Scholar]
  24. Ward T. T., Thomas R. G., Fye C. L., Arbeit R., Coltman C. A., Jr, Craig W., Dana B. W., Finegold S. M., Lentino J., Penn R. L. Trimethoprim-sulfamethoxazole prophylaxis in granulocytopenic patients with acute leukemia: evaluation of serum antibiotic levels in a randomized, double-blind, placebo-controlled Department of Veterans Affairs Cooperative Study. Clin Infect Dis. 1993 Sep;17(3):323–332. doi: 10.1093/clinids/17.3.323. [DOI] [PubMed] [Google Scholar]
  25. Winston D. J., Ho W. G., Bruckner D. A., Gale R. P., Champlin R. E. Ofloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients. Am J Med. 1990 Jan;88(1):36–42. doi: 10.1016/0002-9343(90)90125-w. [DOI] [PubMed] [Google Scholar]
  26. van de Leur J. J., Vollaard E. J., Janssen A. J., Dofferhoff A. S. Concentration of pefloxacin in feces during infection prophylaxis in neutropenic patients. Antimicrob Agents Chemother. 1995 May;39(5):1182–1184. doi: 10.1128/aac.39.5.1182. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES